Penetration of moxifloxacin in bronchial secretions in hospitalised patients with acute exacerbation of COPD

Trial Profile

Penetration of moxifloxacin in bronchial secretions in hospitalised patients with acute exacerbation of COPD

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2015

At a glance

  • Drugs Moxifloxacin (Primary)
  • Indications Chronic obstructive pulmonary disease; Respiratory tract infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 31 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top